menu
    • menu
    [{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Tango Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"BCTG Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ BCTG Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ BCTG Acquisition Corp"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tango Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tango Therapeutics

    Menu

    Tango Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Reports Positive Data for TNG462 in PRMT5 Development Program

                            Details : TNG462 is an investigational stage MTA-cooperative PRMT5 inhibitor, in ongoing phase 1/2 clinical trial for multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer.

                            Product Name : TNG462

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program

                            Details : TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.

                            Product Name : TNG348

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2024

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Doses First Patient in Phase 1/2 Trial Of TNG348 for Cancers

                            Details : TNG348 is a selective USP1 inhibitor in phase 1/2 trials, tested as a single agent and with olaparib for treating BRCA1/2-mutant or other HRD+ cancers.

                            Product Name : TNG348

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 01, 2024

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG908

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Nextech

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces $80 Million Private Placement Financing

                            Details : The proceeds are expected to enable rapid expansion across multiple tumor types for the TNG908 and TNG462 PRMT5 programs, as well as maintain funding through proof-of-concept for each of its clinical-stage programs as the Company awaits clinical data.

                            Product Name : TNG908

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 08, 2023

                            Lead Product(s) : TNG908

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Nextech

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid...

                            Details : TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor, being investigated for the treatment of patients with MTAP-deleted solid tumors and is previously granted Fast Track designation by the U.S. Food and Drug Administration.

                            Product Name : TNG462

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 07, 2023

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG260,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients with STK11-Mutant Cance...

                            Details : TNG260 is a first-in-class inhibitor of the CoREST complex (Co-repressor of Repressor Element-1 Silencing Transcription) being developed in combination with pembrolizumab in patients with STK11-mutant cancers.

                            Product Name : TNG260

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 24, 2023

                            Lead Product(s) : TNG260,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 In...

                            Details : TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), is being developed for the treatment of BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers.

                            Product Name : TNG348

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2023

                            Lead Product(s) : TNG348,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG908

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of...

                            Details : TNG908 is administered orally, a selective PRMT5 inhibitor that drives tumor regression, it is being developed for the treament of MTAP-deleted glioblastoma (GBM).

                            Product Name : TNG908

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : TNG908

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG260

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Clas...

                            Details : TNG260 is a first-in-class inhibitor of the CoREST complex ( Co-repressor of Repressor Element-1 Silencing Transcription), being investingated for the treatment of STK11-mutant cancers.

                            Product Name : TNG260

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 04, 2023

                            Lead Product(s) : TNG260

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Tango Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additi...

                            Details : In preclinical studies, TNG462 is 45X selective for MTAP-deletions (3-fold greater than TNG908) and 20 times more potent than TNG908, which may provide a wider therapeutic index and stronger target inhibition than TNG908.

                            Product Name : TNG462

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 25, 2023

                            Lead Product(s) : TNG462

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth